Premium
Large‐scale plasma proteomic profiling identifies a high‐performance biomarker panel for Alzheimer's disease screening and staging
Author(s) -
Jiang Yuanbing,
Zhou Xiaopu,
Ip Fanny C.,
Chan Philip,
Chen Yu,
Lai Nicole C.H.,
Cheung Kit,
Lo Ronnie M.N.,
Tong Estella P.S.,
Wong Bonnie W.Y.,
Chan Andrew L.T.,
Mok Vincent C.T.,
Kwok Timothy C.Y.,
Mok Kin Y.,
Hardy John,
Zetterberg Henrik,
Fu Amy K.Y.,
Ip Nancy Y.
Publication year - 2022
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1002/alz.12369
Subject(s) - proteome , biomarker , endophenotype , neurodegeneration , disease , blood proteins , medicine , oncology , alzheimer's disease , computational biology , bioinformatics , biology , neuroscience , genetics , cognition
Blood proteins are emerging as candidate biomarkers for Alzheimer's disease (AD). We systematically profiled the plasma proteome to identify novel AD blood biomarkers and develop a high‐performance, blood‐based test for AD. Methods We quantified 1160 plasma proteins in a Hong Kong Chinese cohort by high‐throughput proximity extension assay and validated the results in an independent cohort. In subgroup analyses, plasma biomarkers for amyloid, tau, phosphorylated tau, and neurodegeneration were used as endophenotypes of AD. Results We identified 429 proteins that were dysregulated in AD plasma. We selected 19 “hub proteins” representative of the AD plasma protein profile, which formed the basis of a scoring system that accurately classified clinical AD (area under the curve = 0.9690–0.9816) and associated endophenotypes. Moreover, specific hub proteins exhibit disease stage‐dependent dysregulation, which can delineate AD stages. Discussion This study comprehensively profiled the AD plasma proteome and serves as a foundation for a high‐performance, blood‐based test for clinical AD screening and staging.